TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, today announced that Ronan Levy has resigned as Director of the Company and Paula Amy…


Previous articlePT362 – Cory Firth – Psychedelic Storytelling: Transforming Out Loud
Next articleNuminus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022